Impact of Angiotensin Blockade on Development of Chronic Lung Allograft Dysfunction
Journal of Pharmacy Practice · 2024
DOI: 10.1177/08971900231213699 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2024. Verfasst von Spenser E January und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
The renin-angiotensin-aldosterone system (RAAS) is responsible for a multitude of physiological functions, including immunological effects such as promotion of TGF-β and upregulation of IL-6 and IL-8 which are also implicated in the development of chronic lung allograft dysfunction (CLAD). Blockade of the RAAS pathway in pre-clinical models has demonstrated a decrease in these cytokines and pulmonary neutrophil recruitment.
Objective
This study sought to evaluate whether use of RAAS inhibitor (RAASi) in lung transplant recipients impacted CLAD-free survival.
Methods
In this retrospective, single-center study, 35 lung transplant recipients who received a RAASi post-transplant were compared to 70 lung transplant recipients not exposed to a RAASi and were followed for up to 5 years post-transplant.
Results
The incidence of CLAD did not differ based on RAASi treatment (34.3% in RAASi vs 38.6%, P-value .668). This was confirmed with a multivariable Cox proportional hazards model with RAASi initiation as a time-varying covariate (RAASi hazard ratio of 1.01, P-value .986). Incidence of hyperkalemia and acute kidney injury were low in the RAASi group.
Conclusions
This study demonstrated no association between post-transplant RAASi use and decreased risk of CLAD development. RAASi were also well tolerated in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, USA.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
ORCID-Profile: Spenser E January
Förderung
- NHLBI NIH HHS
Zitieren
APA
January, S. E., Hubbard, J., Fester, K. A., Dubrawka, C. A., Vazquez Guillamet, R., Kulkarni, H. S., & Hachem, R. R. (2024). Impact of Angiotensin Blockade on Development of Chronic Lung Allograft Dysfunction. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900231213699
Vancouver
January SE, Hubbard J, Fester KA, Dubrawka CA, Vazquez Guillamet R, Kulkarni HS, et al. Impact of Angiotensin Blockade on Development of Chronic Lung Allograft Dysfunction. Journal of Pharmacy Practice. 2024. doi:10.1177/08971900231213699
BibTeX
@article{January2024,
author = {January, Spenser E and Hubbard, Julie and Fester, Keith A and Dubrawka, Casey A and Vazquez Guillamet, Rodrigo and Kulkarni, Hrishikesh S and Hachem, Ramsey R},
title = {Impact of Angiotensin Blockade on Development of Chronic Lung Allograft Dysfunction},
journal = {Journal of Pharmacy Practice},
year = {2024},
doi = {10.1177/08971900231213699}
}
EUVIMED